v3.26.3
Accrued Expenses and Other Current Liabilities
 9 Months Ended
Sep. 30, 2026
Accrued Liabilities and Other Liabilities [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands): 
As of
September 30, 2026December 31, 2025
Research and development$6,316 $7,270 
License and milestones10,000 — 
Compensation and benefits4,357 4,132 
General and administrative810 682 
Royalty payment— 327 
Lease liability, current153 392 
Total accrued expenses and other current liabilities$21,636 $12,803 

As of September 30, 2026, the $10.0 million development milestone due upon the dosing of the first patient in a phase 3 trial of abdakibart was considered probable of achievement and is included in accrued expenses and other current liabilities in the accompanying unaudited condensed consolidated balance sheet.